Cortisol secretion and Alzheimer's disease progression

Biol Psychiatry. 1997 Dec 1;42(11):1030-8. doi: 10.1016/s0006-3223(97)00165-0.

Abstract

Background: Mild hypercortisolemia is a frequent concomitant of Alzheimer's disease (AD). In an effort to ascertain the relationship between serum cortisol concentration (CORT) and disease progression, aging, and survival, we followed 9 persons with AD, ages from 56 to 84 years, from an original cohort of 19 enrollees with serial cognitive testing and CORT determinations.

Methods: The cognitive instrument was a modification of the Alzheimer's Disease Assessment Scale-Cognitive (mADAS-COG). Serum cortisol determinations were performed at noon, and an Afternoon Cortisol Test (ACT) was used to obtain an estimate of average CORT.

Results: Baseline 12:00 hours CORT but not ACT correlated significantly with the change in mADAS-COG (r = .90, p < .01). ACT levels increased as the mADAS-COG increased over time (p = .037), by 0.156 +/- 0.06 microgram/dL for each one-point increase (indicating greater impairment) in cognitive test score. ACT levels did not increase significantly simply with aging. For the entire cohort of 19 subjects, neither baseline ACT nor 12:00 hours CORT was significantly related to survival.

Conclusions: Hypercortisolemia in AD appears related to the clinical progression of the disease, but not to aging or length of survival.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Aging / blood
  • Alzheimer Disease / blood*
  • Alzheimer Disease / psychology*
  • Disease Progression
  • Female
  • Humans
  • Hydrocortisone / blood*
  • Male
  • Middle Aged
  • Neurobehavioral Manifestations
  • Psychiatric Status Rating Scales
  • Survival

Substances

  • Hydrocortisone